Acumen Pharmaceuticals Inc (ABOS)
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for Alzheimer’s disease. Its lead candidate is Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 designed to target soluble amyloid-beta oligomers. The program has completed a phase 1 study, INTERCEPT-AD, and is being evaluated in the phase 2 ALTITUDE-AD trial. Acumen also has a collaboration and license agreement with Halozyme, Inc. related to a subcutaneous formulation of Sabirnetug. Founded in 1996, the company is headquartered in Newton, Massachusetts, and its common stock trades on the NASDAQ under the ticker ABOS.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ABOS
|
$2.94
|
11.1% Upside
|
Fair
|
$7.60
|
186.8% Upside
|
Bargain
|
Weak
|
0.0%
|
November 16, 2026
|
3.3x
|
191.6 M
|
108.8 M
|
14.2%
|
51.2%
|
-6.4
|
87.4%
|
